

# Advances in Radiation Oncology

## Practice considerations for proton beam radiotherapy of uveal melanoma during the COVID-19 pandemic: PTCOG Ocular experience --Manuscript Draft--

<b>Manuscript Number:</b>	ADVANCESRADONC-D-20-00108
<b>Article Type:</b>	Brief Opinion
<b>Section/Category:</b>	COVID-19
<b>Corresponding Author:</b>	Kavita K. Mishra, M.D., M.P.H. University of California San Francisco San Francisco, CA UNITED STATES
<b>First Author:</b>	Kavita K. Mishra, M.D., M.P.H.
<b>Order of Authors:</b>	Kavita K. Mishra, M.D., M.P.H. Armin Afshar, MD, MBA Juliette Thariat, MD, PhD Helen A Shih, MD, MS, MPH Jessica E Scholey, MA Inder K Daftari, PhD Andrzej Kacperek, PhD Alessia Pica, MD Jan Hrbacek, PhD Remi Dendale, MD Alejandro Mazal, PhD Jens Heufelder, PhD Devron H. Char, MD Wolfgang A.G. Sauerwein, MD, PhD Damien C Weber, MD Bertil E Damato, MD, PhD
<b>Abstract:</b>	<p>Uveal melanoma (UM) is a rare but life-threatening cancer of the eye. In light of the COVID-19 pandemic, hospitals and proton eye therapy facilities must analyze several factors to ensure appropriate treatment protocols for patients and provider teams. Practice considerations to limit COVID-19 transmission in the proton ocular treatment setting for UM are necessary. The Particle Therapy Co-Operative Group (PTCOG) is the largest international community of particle/proton therapy providers. Participating experts are/were affiliated with the member institutions of the PTCOG Ocular subcommittee with long-standing high-volume proton ocular programs. The practices reviewed in this document must be taken in conjunction with local hospital procedures, multidisciplinary recommendations, and regional/national guidelines, as each community may have its unique needs, supplies, and protocols. Importantly, as the pandemic evolves, so will the strategies and recommendations. Given the unique circumstances for UM patients, along with indications of potential ophthalmologic transmission as a result of healthcare providers working in close proximity to patients and intrinsic infectious risk from eyelashes, tears and hair, practice strategies may be adapted to reduce the risk of viral transmission. Certainly, providers and health care systems will continue to examine and provide as safe and effective care as possible for patients in the current environment.</p>

## **Practice considerations for proton beam radiotherapy of uveal melanoma during the COVID-19 pandemic: PTCOG Ocular experience**

Mishra KK, MD MPH<sup>1</sup>, Afshar A, MD MBA<sup>2</sup>, Thariat J, MD PhD<sup>3</sup>, Shih HA, MD MS MPH<sup>4</sup>, Scholey JE, MA<sup>1</sup>, Daftari IK, PhD<sup>1</sup>, Kacperek A, PhD<sup>5</sup>, Pica A, MD<sup>6</sup>, Hrbacek J, PhD<sup>6</sup>, Dendale R, MD<sup>7</sup>, Mazal A, PhD<sup>8</sup>, Heufelder J, PhD<sup>9</sup>, Char DH, MD<sup>10</sup>, Sauerwein W, MD, PhD<sup>11</sup>, Weber DC, MD<sup>6</sup>, Damato BE, MD PhD<sup>12</sup>

<sup>1</sup> Ocular Tumor Proton Therapy Program, Department of Radiation Oncology, University of California San Francisco, San Francisco, CA, USA

<sup>2</sup> Department of Ophthalmology, University of California San Francisco, San Francisco, CA, USA

<sup>3</sup> Department of Radiation Oncology, Centre François Baclesse, Normandie Université, Caen, France

<sup>4</sup> F.H. Burr Proton Therapy Center, Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA

<sup>5</sup> National Proton Therapy Centre, Clatterbridge Cancer Centre, Wirral, United Kingdom

<sup>6</sup> Center for Proton Therapy, Paul Scherrer Institute, Villigen, Switzerland

<sup>7</sup> Institut Curie Proton Therapy Center, Orsay, France

<sup>8</sup> Centro de Protonterapia Quironsalud, Madrid, Spain

<sup>9</sup> BerlinProtonen am HZB, Charité – Universitätsmedizin Berlin, Berlin, Germany

<sup>10</sup> The Tumori Foundation, San Francisco, CA, USA

<sup>11</sup> Department of Radiation Oncology, University Hospital Essen, Essen, Germany

<sup>12</sup> Nuffield Laboratory of Ophthalmology, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom

Corresponding Author:

Kavita K. Mishra, MD MPH

Associate Professor

Director, UCSF Ocular Tumor Proton & Plaque Therapy Program

Department of Radiation Oncology  
University of California San Francisco  
1600 Divisadero Street, H-1031  
San Francisco, CA 94143-1708  
(415) 353-9807 office  
(415) 505-9636 cell  
kavita.mishra@ucsf.edu

Conflict of Interest: None

Short Running Title: COVID-19 and Proton Ocular Therapy Practices

1  
2  
3  
4 **Practice considerations for proton beam radiotherapy of uveal melanoma during**  
5  
6 **the COVID-19 pandemic: PTCOG Ocular experience**  
7  
8  
9

10  
11 Short Running Title: COVID-19 and Proton Ocular Therapy Practices  
12  
13  
14

15  
16 Abstract: Uveal melanoma (UM) is a rare but life-threatening cancer of the eye. In light  
17  
18 of the COVID-19 pandemic, hospitals and proton eye therapy facilities must analyze  
19  
20 several factors to ensure appropriate treatment protocols for patients and provider  
21  
22 teams. Practice considerations to limit COVID-19 transmission in the proton ocular  
23  
24 treatment setting for UM are necessary. The Particle Therapy Co-Operative Group  
25  
26 (PTCOG) is the largest international community of particle/proton therapy providers.  
27  
28 Participating experts are/were affiliated with the member institutions of the PTCOG  
29  
30 Ocular subcommittee with long-standing high-volume proton ocular programs. The  
31  
32 practices reviewed in this document must be taken in conjunction with local hospital  
33  
34 procedures, multidisciplinary recommendations, and regional/national guidelines, as  
35  
36 each community may have its unique needs, supplies, and protocols. Importantly, as  
37  
38 the pandemic evolves, so will the strategies and recommendations. Given the unique  
39  
40 circumstances for UM patients, along with indications of potential ophthalmologic  
41  
42 transmission as a result of healthcare providers working in close proximity to patients  
43  
44 and intrinsic infectious risk from eyelashes, tears and hair, practice strategies may be  
45  
46 adapted to reduce the risk of viral transmission. Certainly, providers and health care  
47  
48 systems will continue to examine and provide as safe and effective care as possible for  
49  
50 patients in the current environment.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4 **Practice considerations for proton beam radiotherapy of uveal melanoma**  
5  
6 **during the COVID-19 pandemic: PTCOG Ocular experience**  
7  
8  
9

10  
11  
12 Uveal melanoma (UM) threatens patients with loss of vision, a painful eye needing  
13 enucleation (i.e., amputation), and metastatic disease. Metastases develop in almost  
14  
15 50% of patients, usually involve the liver and rarely respond to treatment so that most  
16  
17 patients die within a year of onset of systemic symptoms. The first choice of ocular  
18  
19 treatment is radiotherapy, reserving enucleation for patients with advanced disease.  
20  
21  
22  
23  
24  
25

26  
27 In light of the current COVID-19 pandemic, local hospitals and proton radiotherapy  
28  
29 facilities are considering several factors as protocols are developed for ocular oncology  
30  
31 patients, including (a) national/regional/local medical system status and quarantine  
32  
33 policies; (b) internal hospital COVID-19 policies; (c) multidisciplinary dialogue amongst  
34  
35 ophthalmology and radiation oncology; and (d) status of protective equipment for  
36  
37 patients, staff, and providers.  
38  
39  
40  
41  
42  
43

44 The American Association of Ophthalmic Oncologists and Pathologists (AAOOP)  
45  
46 recently issued guidelines for the management and triage of ocular oncology cases  
47  
48 during the COVID-19 pandemic.<sup>1</sup> Certain ocular conditions will require ‘emergent’ care  
49  
50 to be performed within 24 hours or as soon as possible to preserve life and/or sight and  
51  
52 ‘urgent’ to be performed within the week, considering the availability of resources. The  
53  
54 treatment for uveal melanomas is classified as ‘semi-urgent’, that is, needing to be  
55  
56 performed within 1-2 months, considering the availability of resources. The guidelines  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4 also indicate that in some cases, the balance may shift to delayed care being more  
5  
6 appropriate for safety and conservation of limited resources.  
7  
8  
9

10  
11 The AAOOP practice guidelines state the importance of recognizing that there is risk for  
12  
13 transmission of SARS-CoV-2 during patient care, even by asymptomatic individuals.  
14

15  
16 The risk to patients, physicians and staff, and the community at large “must therefore be  
17  
18 balanced with the necessity for urgent care.” Reports from China indicate potential  
19  
20 ophthalmologic transmission as a result of healthcare providers working in close  
21  
22 proximity to patients and intrinsic infectious risk from eyelashes, tears and hair.<sup>2</sup> In  
23  
24 addition, one group noted that a third of their clinically confirmed COVID-19 patients had  
25  
26 ocular abnormalities, and these commonly occurred in patients with a more severe form  
27  
28 of the disease.<sup>3</sup>  
29  
30  
31  
32  
33

34  
35 Currently, high-priority cancer patients are being identified using several factors, to  
36  
37 include those: (1) who are deemed critical (unstable, unbearable suffering); (2) whose  
38  
39 condition is immediately or potentially life-threatening; and (3) who have access to  
40  
41 effective treatment. Importantly, given the complexity of ocular oncology care, patient-  
42  
43 specific risk factors, and capacity issues, guidelines will need to remain flexible, be  
44  
45 revisited, and exceptions will occur.<sup>4-5</sup> Clinicians will certainly have to evaluate patients  
46  
47 on a case-by-case basis and balance the potential risk and severity of outcomes,  
48  
49 including loss of vision, loss of an eye and systemic disease progression which  
50  
51 uniformly leads to risk of death.  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4 Specifically, the UK National Health Service has included as Priority level 1 cancer  
5 patients with curative therapy with a high (>50%) chance of success with time sensitive  
6 therapy. Radiation patients specifically are split into five levels, with Priority 1 RT  
7 patients including those with category 1 (rapidly proliferating) tumors for whom timely  
8 curative intent radiotherapy is needed where there is little or no scope for compensation  
9 of gaps and/or treatment delay. Priority level 3 radiation patients include those with  
10 category 2 (less aggressive) tumors where RT is the first definitive treatment.<sup>5</sup>  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21

22 Uveal melanoma meets these high-priority criteria because: (1) it is highly lethal, with  
23 approximately an overall 50% rate of metastasis<sup>6,7</sup>; (2) outcomes are potentially worse if  
24 ocular treatment is delayed<sup>6-8</sup>; and (3) ocular radiotherapy is highly effective at  
25 achieving local tumor control (e.g., >95% rate of local tumor control after 4-5 fractions of  
26 proton beam radiotherapy (PBRT)).<sup>6,9,10</sup> Noteworthy, proton eye therapy for UM is  
27 delivered with significant hypofractionation (12-15 Gray Equivalent fractional dose) and  
28 thus in full accordance with the recently released radiotherapy guidelines during the  
29 pandemic.<sup>11,12</sup>  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43

44 In this document, we list practice considerations to limit COVID-19 transmission in the  
45 proton ocular treatment setting for UM. Participating co-authors are/were affiliated with  
46 member institutions of the Particle Therapy Co-Operative Group (PTCOG) Ocular  
47 subcommittee with long-standing high-volume proton ocular programs.<sup>13</sup> The below  
48 comments do not supersede those of local hospitals and communities, as each of which  
49 will have its unique needs and practices, and these may change as the pandemic  
50 evolves.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7  
8  
9 *Uveal melanoma proton radiotherapy general practice considerations:*

10  
11  
12  
13  
14 **1. Adhere to clinical guidelines to minimize infectious transmission risk:**

15  
16 Minimize face-to-face appointments by utilizing telehealth technology and by  
17  
18 increasing efficiency when in-person appointments are required. Consider  
19  
20 measures to limit waiting room stays (e.g., having patients wait outside/in their  
21  
22 car and contacting them when they are due to be seen). Follow local protocols on  
23  
24 daily symptomatic/temperature screening, testing, and isolation. Minimize  
25  
26 additional visitors unless required. Use appropriate personal protective  
27  
28 equipment and maintain physical distancing.  
29  
30  
31  
32

33  
34  
35  
36 **2. Use clinical judgement:** Balance the risk of delayed, sub-optimal treatment with  
37  
38 the risk of transmission of COVID-19. Consider risk factors for patients who may  
39  
40 be predisposed to severe illness due to age, comorbidities, and/or  
41  
42 immunosuppression. Use the RADS principle to minimize risk (Remote, Avoid,  
43  
44 Defer, Shorten).<sup>14</sup>  
45  
46  
47

48  
49  
50  
51 **3. Consider alternatives:** Enucleation, other types of radiation therapy, or  
52  
53 surveillance may or may not be appropriate in select cases, depending on  
54  
55 OR/personnel/equipment availability, tumor/patient factors, physician  
56  
57 assessment, type/severity of risk, etc. In some patients (e.g., those with small,  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4 genetically favorable tumors or localized iris tumors), outcomes may not be  
5  
6 compromised if treatment is delayed until the risk of infection has subsided. For  
7  
8 patients who have undergone surgical tantalum clip placement already, clinical  
9  
10 consideration must be given to timing of definitive treatment. In addition, if  
11  
12 travel/hotel stay for 4-5 days treatment course is required for patients, this may or  
13  
14 may not be feasible given local conditions/national quarantine policies.<sup>15</sup>  
15  
16  
17  
18  
19  
20

21 Importantly, it is not known whether a delay of several months significantly  
22  
23 increases any risk of metastasis for an individual patient. This uncertainty exists  
24  
25 even when tumor biopsy has been performed, whatever the results of genetic  
26  
27 tumor analysis. The risk and benefits of immediate versus delayed treatment  
28  
29 need to be communicated with the patient when obtaining informed consent for  
30  
31 urgent or deferred therapy.  
32  
33  
34  
35  
36  
37

38 *Regarding specific potential considerations for UM PBRT procedures:*  
39  
40  
41  
42

- 43 1. **Hypofractionation is already standard practice for UM proton RT** with a total  
44  
45 of 4-5 fractions delivered in one week, hence shortening the window of potential  
46  
47 exposure and compliant with current emergency guidelines for RT.<sup>11,12</sup>  
48  
49  
50
- 51 2. **Wear protective gear in line with facility guidelines** (i.e., gloves, mask, face  
52  
53 shield, goggles, hair cover, etc.) when in close physical proximity to the patient.  
54  
55  
56 Consider local guidelines on proper dress and avoidance of accessories, etc.  
57  
58  
59  
60  
61  
62  
63  
64  
65



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

3. **Apply infection precautions when placing eye drops and eyelid retractors.**

Contact with ocular mucosa and tears is potentially contagious and technique in handling of drops/retractors should be similar to contact risk precautions for other bodily fluid. If possible, stand to one side of the patient when instilling eye drops or inserting and removing eyelid retractors to limit direct breathing space overlap and fluid exposure.

Limit team members in immediate vicinity during such procedures.

Transpalpebral technique without lid retractors may be appropriate for certain tumors.<sup>16</sup> Conduct appropriate cleaning and/or disposal of retractors.

4. **Clean immobilization head mask and mask frame thoroughly** with antiseptic and store each mask separately in designated areas/individual bags per hospital guidelines. The treatment chair and parts of the machinery as well may require appropriate cleaning/disposable coverings as per hospital guidelines.

5. **Clean bite blocks thoroughly and/or consider alternatives** (i.e. as may be done with claustrophobic patients). A chin rest (similar to that used for a slit lamp exam) or chin strap may be an option to minimize salivary fluid and maximize positioning, reproducibility, and cleaning. Close attention must be paid to daily set-up and proton beam safety margins can be increased to avoid geographic

miss as needed. Bite blocks should be handled with proper precautions in placement/removal and cleaned thoroughly after each fraction if/when used.

6. **Limit physical aperture adjustments** by considering an increased margin (~0.5-1 mm) in advance to avoid any potential adjustments for materials in close contact with the patient. All materials must be disinfected per facility guidelines, especially if transferred between team members/clinic-work areas.
7. **Follow masking policy**, which varies between centers. If resources allow, masks may be worn both by the patient being treated and by any staff who may come into close contact with each other and with machinery. Masks may need to be stored/cleaned/reused if supply is limited. Follow hospital/national guidelines on proper surgical mask and/or N95/FFP2 respirator use for ophthalmic procedures based on exposure risk and supplies.<sup>2,17</sup>
8. **Sanitize** the patient's hands prior to set-up/entry, ideally upon arrival to the treatment environment and/or within the treatment room as per local supplies and guidelines. Staff must also sanitize their own hands between patient set-ups, according to local protocols. Plan additional time per patient to allow proper sanitization.
9. **Organize clinic flow** to maximize distance between providers/team members and to enhance efficiency, thereby minimizing patient time in clinic. Limit the

1  
2  
3  
4 number of staff involved with direct patient contact and optimize teams to  
5  
6 minimize number at risk at any time.  
7  
8  
9

10  
11 **10. Consider testing** patients as per hospital guidelines and supplies availability.  
12

13  
14 For patients testing positive for SARS-CoV-2, it may be most appropriate to delay  
15  
16 proton eye treatment within the appropriate clinical window until negative testing  
17  
18 status is confirmed to reduce risk to patients and the provider team. If/when  
19  
20 antibody serology testing becomes available, provider teams may be tested per  
21  
22 local guidelines and appropriate staffing decisions can be made. If a COVID+  
23  
24 patient must be treated, follow hospital guidelines regarding timing, PPE, and  
25  
26 protocols to separate the circuit of COVID+ patients (i.e. isolated path, end of day  
27  
28 treatment, trained team in PPE, etc.).  
29  
30  
31  
32  
33

34  
35 **11. Iris tumors:** Treatment of select iris melanomas with radiation therapy may be  
36  
37 non-urgent and delayed for 2-3 months.<sup>1</sup> Some iris tumors may be urgent,  
38  
39 especially if there is rapid growth or secondary glaucoma, and will require  
40  
41 physician assessment to determine degree of urgency. Iris melanomas with  
42  
43 secondary glaucoma could be due to a ring melanoma and enucleation may be  
44  
45 the recommended treatment based on current/local circumstances and would  
46  
47 require the appropriate ophthalmic assessment.  
48  
49  
50  
51  
52

53  
54 **12. Other ocular tumors:** Conjunctival tumors, angiomas, hemangiomas, metastatic  
55  
56 ocular disease, and other ocular conditions should be evaluated separately to  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4 determine best safe and effective course of action per AAOOP, multidisciplinary,  
5  
6 and other appropriate guidelines.  
7  
8  
9

10  
11 If tantalum ring surgery is not possible because of limited operating room facilities, there  
12 may be a limited role under special circumstances for 'clipless' planning (as is done with  
13  
14 some benign conditions, such as hemangiomas).<sup>18</sup> Safety margins are increased to  
15  
16 ensure adequate treatment of the entire tumor and additional imaging may be  
17  
18 beneficial.<sup>19</sup> This is not standard of care, and if this strategy is pursued the provider  
19  
20 team must use appropriate clinical judgement and ensure appropriate  
21  
22 discussion/documentation of potential tumor control, visual, or other toxicity outcomes.  
23  
24 The risks and benefits of these measures should be fully discussed with patients to  
25  
26 ensure informed consent. Limited OR time may also affect availability of other  
27  
28 alternatives such as enucleation, plaque therapy, or endoresection.  
29  
30  
31  
32  
33  
34  
35  
36  
37

38 The COVID-19 pandemic is a fluid situation and current best practices and institutional  
39  
40 guidelines may need to be adjusted as resources may become limited, personnel may  
41  
42 be on quarantine/sick leave, and different scenarios are observed.<sup>20-24</sup> Given the  
43  
44 unique potential for viral spread in ophthalmology procedures and the fact that  
45  
46 hypofractionated proton eye treatment is delivered over only one week, thoughtful  
47  
48 clinical practices are essential during this pandemic and should be considered carefully.  
49  
50  
51 Certainly, providers and hospital systems on the front lines will continue to examine and  
52  
53 provide as safe and effective care as possible for patients in the current environment.  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12 **References:**  
13

- 14 1. American Association of Ophthalmic Oncologists and Pathologists (AAOOP),  
15 March 2020, <http://www.aaoop.org/wp-content/uploads/2020/03/AAOOP->  
16 [COVID19-Oncology-Considerations-UPDATED.pdf](http://www.aaoop.org/wp-content/uploads/2020/03/AAOOP-)  
17  
18
- 19 2. Lai THT, Tang EWH, Chau SKY, et al. Stepping up infection control measures in  
20 ophthalmology during the novel coronavirus outbreak: an experience from Hong  
21 Kong [published online ahead of print, 2020 Mar 3]. *Graefes Arch Clin Exp*  
22 *Ophthalmol.* 2020;10.1007/s00417-020-04641-8. doi:10.1007/s00417-020-  
23 04641-8.  
24  
25
- 26 3. Ping W, Duan F, Luo C, et al. Characteristics of ocular findings of patients with  
27 coronavirus disease 2019 (COVID-19) in Hubei Province, China. *JAMA*  
28 *Ophthalmology*, March 31, 2020 online, doi:10.1001/jamaophthalmol.2020.1291  
29  
30
- 31 4. National Institute for Health and Care Excellence (NICE). COVID-19 rapid  
32 guideline: delivery of radiotherapy. March 28, 2020.  
33 [www.nice.org.uk/guidance/ng162](http://www.nice.org.uk/guidance/ng162).  
34  
35
- 36 5. National Health Service (NHS) UK. Clinical guide for the management of non-  
37 coronavirus patients requiring acute treatment: Cancer. March 23, 2020 Version  
38 2, Publication approval reference 001559.  
39 [https://www.england.nhs.uk/coronavirus/wp-](https://www.england.nhs.uk/coronavirus/wp-content/uploads/sites/52/2020/03/specialty-guide-acute-treatment-cancer-23-march-2020.pdf)  
40 [content/uploads/sites/52/2020/03/specialty-guide-acute-treatment-cancer-23-](https://www.england.nhs.uk/coronavirus/wp-content/uploads/sites/52/2020/03/specialty-guide-acute-treatment-cancer-23-march-2020.pdf)  
41 [march-2020.pdf](https://www.england.nhs.uk/coronavirus/wp-content/uploads/sites/52/2020/03/specialty-guide-acute-treatment-cancer-23-march-2020.pdf)  
42  
43
- 44 6. Mishra KK Quivey JM, Daftari IK, et al. Uveal Melanoma. In: Hoppe R, Phillips  
45 TL, Roach M. editors. *Leibel and Phillips Textbook of Radiation Oncology*. 3rd  
46 ed. Philadelphia: Elsevier Inc., 2010:1400-21.  
47  
48
- 49 7. Kaliki S, Shields CL. Uveal melanoma: Relatively rare but deadly cancer. *Eye*  
50 2017;31:241-257.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

- 1  
2  
3  
4 8. Straatsma BR, Diener-West M, Caldwell R, et al. for the Collaborative Ocular  
5 Melanoma Study Group. Mortality after deferral of treatment or no treatment for  
6 choroidal melanoma. *Am J Ophthalmol* 2003;136:47-54.  
7  
8
- 9 9. Damato, Kacperek A, Chopra M, et al. Proton beam radiotherapy of choroidal  
10 melanoma: the Liverpool-Clatterbridge experience. *Int J Radiat Oncol Biol Phys*  
11 2005;62:1405-11.  
12  
13
- 14 10. Chang MY, McCannel TA. Local treatment failure after globe-conserving therapy  
15 for choroidal melanoma. *Br J Ophthalmol* 2013;97:804-811.  
16  
17
- 18 11. Hrbacek J, Mishra KK, Kacperek A, et al. Practice patterns analysis of ocular  
19 proton therapy centers: The international OPTIC survey, *Int J Radiat Oncol Biol*  
20 *Phys*, 2016; 95: 336-343.  
21  
22
- 23 12. Fillippi AR, Russi E, Magrini SM, et al. COVID-19 outbreak in northern Italy: First  
24 practical indications for radiotherapy departments. *Int J Radiat Oncol Biol Phys*  
25 March 2020, doi: <https://doi.org/10.1016/j.ijrobp.2020.03.007>.  
26  
27
- 28 13. Kacperek A. Ocular Proton Therapy Centers. In: Linz U, editor. *Ion Beam*  
29 *Therapy: Fundamentals, Technology, Clinical Applications*. Heidelberg/Berlin:  
30 Springer-Verlag, 2012:149-178.  
31  
32
- 33 14. Spratt D, Dess R et al. (2020) Prostate Cancer Radiotherapy Recommendations  
34 in Response to COVID-19. *Advances in Radiation Oncology*,  
35 [https://www.astro.org/ASTRO/media/ASTRO/Daily%20Practice/PDFs/COVID-](https://www.astro.org/ASTRO/media/ASTRO/Daily%20Practice/PDFs/COVID-Zaorsky-et-al(ADRO).pdf)  
36 [Zaorsky-et-al\(ADRO\).pdf](https://www.astro.org/ASTRO/media/ASTRO/Daily%20Practice/PDFs/COVID-Zaorsky-et-al(ADRO).pdf)  
37  
38
- 39 15. National Health Service (NHS) UK. Management of proton beam therapy  
40 referrals in response to COVID-19. Publication approval 001559. April 3, 2020.  
41 [https://www.england.nhs.uk/coronavirus/wp-](https://www.england.nhs.uk/coronavirus/wp-content/uploads/sites/52/2020/03/C0115-management-of-proton-beam-therapy-referrals-3-april-2020.pdf)  
42 [content/uploads/sites/52/2020/03/C0115-management-of-proton-beam-therapy-](https://www.england.nhs.uk/coronavirus/wp-content/uploads/sites/52/2020/03/C0115-management-of-proton-beam-therapy-referrals-3-april-2020.pdf)  
43 [referrals-3-april-2020.pdf](https://www.england.nhs.uk/coronavirus/wp-content/uploads/sites/52/2020/03/C0115-management-of-proton-beam-therapy-referrals-3-april-2020.pdf)  
44  
45
- 46 16. Konstantinidis L, Roberts D, Errington RD, et al. Transpalpebral proton beam  
47 radiotherapy of choroidal melanoma. *Br J Ophthalmol* 2005;99:232-235.  
48  
49
- 50 17. Public Health England. COVID-19: Infection prevention and control (IPC).  
51 Published Jan 20, 2020, updated April 6, 2020.  
52 [https://www.gov.uk/government/publications/wuhan-novel-coronavirus-infection-](https://www.gov.uk/government/publications/wuhan-novel-coronavirus-infection-prevention-and-control)  
53 [prevention-and-control](https://www.gov.uk/government/publications/wuhan-novel-coronavirus-infection-prevention-and-control)  
54  
55
- 56 18. Chan RVP, Yonekawa Y, Lane AM, et al. Proton beam irradiation using a light-  
57 field technique for the treatment of choroidal hemangiomas. *Ophthalmologica*  
58 2010;224:209–216.  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

19. Nguyen H-G, Sznitman R, Maeder P, et al. Personalized anatomic eye model from T1-weighted volume interpolated gradient echo magnetic resonance imaging of patients with uveal melanoma. *Int J Radiat Oncol Biol Phys*, 2018;102(4): 813-820.

20. Li, Q, Guan X, Wu P, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia. *N Engl J Med* 2020; 382(13):1199-1207.

21. Rosenbaum, L. Facing Covid-19 in Italy — Ethics, logistics, and therapeutics on the epidemic’s front line. *N Engl J Med* 2020 Mar 18; DOI: 10.1056/NEJMp2005492

22. Guan W, Ni Z-Y, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. *N Engl J Med* 2020 Feb 28; DOI: 10.1056/NEJMoa2002032

23. Xia Y, Jin R, Zhao J, et al. Risk of COVID-19 for cancer patients. *Lancet Oncol* April 2020; 21(4):e180. [https://doi.org/10.1016/S1470-2045\(20\)30150-9](https://doi.org/10.1016/S1470-2045(20)30150-9)

24. Lancet. COVID-19: Protecting health-care workers. *The Lancet* 2020; 395(10228). [https://doi.org/10.1016/S0140-6736\(20\)30644-9](https://doi.org/10.1016/S0140-6736(20)30644-9)